Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785226 · ClinicalTrials.gov registry record · Phase 1
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1 study of Advanced Cancer, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 10
- Study locations
NCT00785226 is a Phase 1 study of Advanced Cancer that has completed, run by Bayer. The registered enrollment target is 62 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT00785226, a Phase 1 study of Advanced Cancer, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG RDEA119
Study Locations (10)
New York
- New York Oncology Hematology, PC - Albany
- Roswell Park Cancer Institute - Buffalo
- James P. Wilmot Cancer Center - Rochester
Texas
- Texas Oncology - Baylor Charles A. Simmons Cancer Center - Dallas
- Texas Oncology-Tyler - Tyler
California
- USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center - Los Angeles
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Pennsylvania
- UPenn - Philadelphia
South Carolina
- Greenville Hospital System University Medical Center, (ITOR) - Greenville
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785226
The ClinicalTrials.gov registry entry for NCT00785226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT00785226 reports 10 study locations spanning 7 distinct geographic areas - top geographies include New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT00785226 about?
NCT00785226 is a clinical study titled "RDEA119 and Sorafenib Combination Dose Escalation Study". Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.
What is the current status of trial NCT00785226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-11. Estimated completion is 2012-04.
What conditions does trial NCT00785226 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00785226?
The interventions under investigation include: Sorafenib (DRUG), RDEA119 (DRUG).
Who is sponsoring clinical trial NCT00785226?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00785226 being conducted?
This trial has 10 study locations across California, Nevada, New York, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.